Werewolf Therapeutics, Inc.
corporate_fare Company Profile
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for HOWL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for HOWL spans 10-Q, S-4/A, 8-K, S-4.
Recent high-impact activity:
- Werewolf Q3: $41.9M Cash, Going Concern, Dec 17 Merger Vote
- Werewolf Sets Dec 17 Vote on Ambros Reverse Merger, 12:1-20:1 Reverse Split
- Werewolf Reports WTX-124 Response Rates Up to 37.5% and FDA-Aligned Phase 2 Dose
- Werewolf S-4 Amendment Sets Proxy Vote on $500M Ambros Reverse Merger and $150M PIPE
- Werewolf Files S-4 for Reverse Merger with Ambros: $150M PIPE, 72% Ambros Ownership, CVR for Legacy Assets
Financial Snapshot
Short Interest & Short Volume
6.39 days to coverFINRA reported short interest of 2,128,661 shares in HOWL as of the October 30, 2026 settlement, a 9.7% decrease from the prior period — about 6.4 days to cover at its recent average daily volume. On November 20, 2026, 49.5% of HOWL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.